A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis - Insogna, KL; Briot, K; Imel, EA; Kamenicky, P; Ruppe, MD; Portale, AA (J Bone Miner Res, 2018)
et al.